Opinion|Videos|August 15, 2024
Complications and Prognostic Factors in Uncontrolled Rheumatoid Arthritis
A panel of medical experts discuss complications and prognostic factors in uncontrolled rheumatoid arthritis.
Advertisement
Episodes in this series
Video content above is prompted by the following:
What are typical complications associated with uncontrolled rheumatoid arthritis?
Are there patient prognostic factors that can help determine likelihood of uncontrolled disease vs remission?
Advertisement
Related to this article
Amplio Pharma now planning a phase 2a study after NovoBioJect raised intracellular active methotrexate levels by 38%.
The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
Advertisement
Advertisement
Trending on Rheumatology Live
1
Nipocalimab, Telitacicept, and the Sjögren’s Disease Pipeline
2
Dazodalibep Eases Sjögren’s Dryness via CD40L Blockade: Ghaith Noaiseh, MD
3
Dazodalibep Lowers Sjögren’s Disease Activity: Ghaith Noaiseh, MD
4
INDIGO: Obexelimab Sustains IgG4-RD Flare Control, With John Stone, MD, MPH
5